Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Mathias Lichterfeld · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2022 · $82,537 — Project Summary/Abstract, Immune Control (Project 4) Finding a cure for HIV-1 infection is of particular importance for the growing number of HIV-1-infected infants, children and teenagers who will have to take lifelong antiretroviral therapy if curative treatment options will not be available. Rece…
FRANCOIS VILLINGER · UNIVERSITY OF LOUISIANA AT LAFAYETTE · 2022 · $833,577 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
Suresh B Boppana · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2022 · $270,527 — Project Summary/Abstract The novel coronavirus SARS-CoV-2 (SARS2) pandemic has so far infected greater than 65 million individuals and resulted in almost 850,000 deaths in the US. Although it has been suggested that adaptive immunity plays an important role in improving clinical outcomes of patients…
Lisa Ann Lewis · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2022 · $251,250 — ABSTRACT Gonorrhea affects over 87 million people annually globally. In 2019, over 600,000 cases of gonorrhea were reported to the CDC, a 92% increase since the historic low in the US in 2009. However, the true incidence of cases annually in the US is estimated to be ~1.5 million. The spread of anti…
ERIC T. KOOL · STANFORD UNIVERSITY · 2022 · $425,319 — Work in the last decade from many labs has underlined the critical importance of RNA-mediated cellular pathways, and clear connections of specific RNAs to human health. RNAs are increasingly viewed both as appealing therapeutic targets, and as therapeutic agents themselves. We hypothesize that obtai…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2022 · $240,446 — Project Summary The goal of this Center of Biomedical Research Excellence is to continue our efforts to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approa…
Peter B. Gilbert · FRED HUTCHINSON CANCER CENTER · 2022 · $14,844,618 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial entitled “Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with …
Scott Dexter Boyd · STANFORD UNIVERSITY · 2022 · $440,000 — Primary immune deficiency disorders (PID) affect 1 in 2,000 individuals in the U.S., twice the prevalence of non-Hodgkin lymphoma. PID patients are at risk for severe COVID-19 and impaired responses to vaccination. Research into vaccine boosting in these individuals is clearly of importance for pu…
Marcos Lopez · UNIVERSITY OF PUERTO RICO MED SCIENCES · 2022 · $407,099 — The rapid global spread of SARS-CoV-2 has had a significant impact on the cancer population. SARSCoV-2 infection of hematopoietic stem cell transplant (HSCT) recipients leads to a poor prognosis with a ~68% survival rate. Immune mediated protection is critical to protect the HSCT population. However…
Yang Xu · LUNA LABS USA, LLC · 2022 · $296,833 — Project Summary Significant research has gone into the development of a safe and effective vaccine for HIV-1. Although many strategies have been attempted; none has been successfully established. Even a partially effective vaccine could decrease the number of people who are infected with HIV, furthe…
Guido Ferrari · DUKE UNIVERSITY · 2022 · $5,719,876 — ABSTRACT The ultimate goal of the proposed studies is to contribute to ending the HIV/AIDS epidemic. It has been four decades since the start of the HIV/AIDS epidemic and a protective vaccine or functional cure has been elusive. In 2020, there was an estimated 37.6 million people living with HIV. D…
Monica Banez-Coronel · UNIVERSITY OF FLORIDA · 2022 · $72,556 — Project Summary Repeat expansion mutations cause more than 50 neurodegenerative diseases, including Huntington disease (HD) and C9orf72 amyotrophic lateral sclerosis. Despite intense research, there are no effective treatments for any of these disorders. Repeat expansion mutations are often bidirect…
JOHN J FOXE · UNIVERSITY OF ROCHESTER · 2022 · $213,402 — ABSTRACT School-children with intellectual and developmental disabilities (IDD) are at acute risk for severe COVID-19. Many have compromised immunological and respiratory function, cognitive impairment and complex medical issues. Children with IDD desperately need to attend specialized schools, but …
Mariette Barbier · WEST VIRGINIA UNIVERSITY · 2022 · $204,972 — Project Summary Lyme disease is an endemic tick-borne disease associated with debilitating manifestations such as arthritis, muscle pain, carditis, meningitis, and encephalomyelitis. Despite extensive efforts in the field, there is still no vaccine for the prevention of this infection available for …
GILLIAN L BEAMER · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2022 · $556,566 — PROJECT SUMMARY/ABSTRACT Throughout modern history, tuberculosis (TB) has killed more people than any other infectious disease to date (estimated > 2 billion people over the past 350 years) and TB continues to kill 4,000 patients each day. In 2019 alone, the World Health Organization estimated that …
Jesse Hong-Sae Erasmus · HDT BIO CORPORATION · 2022 · $104,692 — Project Summary While a universal influenza vaccine, providing life-long protective immunity against all current and future drifted and shifted subtypes of influenza virus after 2 or 3 doses, would be a game-changing solution to reducing the global burden of influenza and its associated morbidity an…
JEFFREY M. JACOBSON · CASE WESTERN RESERVE UNIVERSITY · 2022 · $483,000 — Background. Vaccines against SARS-CoV-2 (CoV-2) do not prevent infection and subsequent transmission. Strong evidence now implicates the oral cavity as a primary site of acute CoV-2 infection It is therefore incumbent upon us to search for evidence as to why primary mucosal sites, such as the tongue…
Sebla B. Kutluay · WASHINGTON UNIVERSITY · 2022 · $196,875 — Abstract Virtually every step of HIV-1 replication as well as numerous cellular antiviral defense mechanisms are regulated by viral and cellular RNA-binding proteins (RBPs) that recognize distinct sequence or structural features on viral RNAs. One such interaction takes place between the HIV-1 majo…
Michela Locci · UNIVERSITY OF PENNSYLVANIA · 2022 · $660,497 — SUMMARY Messenger RNA (mRNA) vaccines represent a powerful vaccine approach for the induction of protective immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since this vaccine platform was approved for human use in 2020 for the first time, little is known about …
Scott M Husson · CLEMSON UNIVERSITY · 2022 · $217,771 — Project Summary Circular RNA (circRNA) has important, understudied roles all across physiology and disease. Additionally, circularization of protein-coding RNA is a promising strategy for increasing the duration and quantity of therapeutic protein production and decreasing immunogenicity relative to…